BRCA2 and cancer: Alternatively, it is possible that cells undergoing loss of heterozygosity in BRCA2 mutation carriers undergo apoptosis in the presence of RAD52 S346X variant, due to the persistence of unrepaired DSBs that may suppress tumorigenesis and reduce cancer risk.